Pharmalot... Pharmalittle... Good Morning

Hello, everyone, and how are you today? Another spot of rain is falling on the Pharmalot corporate campus, where we are enduring our usual morning routine of hustling short people off to the schoolhouses and keeping the official mascots fed and quiet. Meanwhile, we are brewing up another cup of stimulation as we dig in for a long day of writing and reading. As for you, no doubt there are meetings and deadlines in the offing. So to get you started, here are some tidbits. Hope your day goes well...

Roche And Lilly Alzheimer's Drugs Chosen For Clinical Trial (Reuters)

Doctors Rethink Use Of Compounding Pharmacies (Wall Street Journal)

Pfizer To Pay $164M To Settle Shareholder Suit Over Celebrex (Reuters)

Glaxo And Aeras Collaborate On TB Vaccine (Pharma Times)

Pharma Is Afraid Of Using Kids In Trials? (Outsourcing Pharma)

Sanofi And Aurobindo Accused Of Overcharging In India (Business Standard)

Sanofi Inks Cancer Deal With MassGen Hospital (Pharma Times)

Merck Opens New Plant In Indonesia (Jakarta Post)

Will A UK Dementia Summit Boost Interest In Research? (BBC)

EDITOR'S NOTE: Please check this post for updates

2 Comments

Oct 10, 2012 - 1:21pm
Pharma companies find enough pediatric patients for a trial when it gives them a 6 month patent extension.
Oct 10, 2012 - 2:14pm
Doc - I was about to say the same thing. One of my many concerns is that the pharms will follow the trend to use children from other countries (such as Lilly's short-term, few numbers of kids from Russia for its pediatric Zyprexa trials), making clinical trials even less valid and more open to fraud.

In this vein, have you read Donald L. Bartlett's and James B. Steele's excellent article, "Deadly Medicine", Vanity Fair, January 2011?